Angiogenesis inhibitors showed no increased risk of arterial dissections or aneurysms in metastatic colorectal cancer patients. The study involved 34,733 patients, with 195 cases matched to 1950 ...

Yes. In 1980 came interferon, in 1981 or 1982 came platelet factor 4. These were the first two. By then we said there are ...

A 2026 review proposes that SFRP4 may inhibit tumor angiogenesis through integrin-linked disruption of Wnt–β-catenin ...

This past February, for example, Sugen, a division of Peapack, NJ-based Pharmacia, announced it was aborting its Phase III colorectal cancer clinical trial of SU5416, as no clinical benefit was found.

Universidad Nacional Autonoma de Mexico and Vian Therapeutics Inc. have synthesized peptides acting as angiogenesis inhibitors reported to be useful for the treatment of cancer, diabetic retinopathy ...